An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

Nivolumab (NIVO) plus low-dose ipilimumab (IPI) has shown a promising survival benefit in first-line treatment of microsatellite instability-high (MSI-H) colorectal cancer. We hypothesized that this regimen might also be beneficial for MSI-H gastric cancer (GC), which accounts for ~5% of all GC case...

Full description

Bibliographic Details
Main Authors: Hisato Kawakami, Shuichi Hironaka, Taito Esaki, Kazuaki Chayama, Masahiro Tsuda, Naotoshi Sugimoto, Shigenori Kadowaki, Akitaka Makiyama, Nozomu Machida, Hidekazu Hirano, Kenro Hirata, Hiroki Hara, Hiroshi Yabusaki, Yoshito Komatsu, Kei Muro
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
gastric cancer
microsatellite instability
nivolumab
ipilimumab
Online Access:https://www.mdpi.com/2072-6694/13/4/805

Internet

https://www.mdpi.com/2072-6694/13/4/805

Similar Items